The companies will collaborate to discover therapeutic small molecule candidates against an oncology target. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.